J Tedroff
Overview
Explore the profile of J Tedroff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hjorth S, Waters S, Waters N, Tedroff J, Svensson P, Fagerberg A, et al.
J Pharmacol Exp Ther
. 2020 Jul;
374(3):404-419.
PMID: 32605972
Here we describe for the first time the distinctive pharmacological profile for (3)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752), a new phenyl-pyrrolidine derivative with regioselective central nervous system transmission-enhancing properties. IRL752 (3.7-150 µmol/kg, s.c.) was...
2.
Hellden A, Panagiotidis G, Johansson P, Waters N, Waters S, Tedroff J, et al.
Eur J Clin Pharmacol
. 2012 Mar;
68(9):1281-6.
PMID: 22399238
Purpose: The influence of the cytochrome P450 enzyme CYP2D6 in the metabolism of the novel dopaminergic stabilizer pridopidine was investigated in healthy Swedish Caucasians. Methods: Six extensive metabolizers (EM) and...
3.
Nichols N, Cimini M, Haas J, Staton B, Tedroff J, Svensson K
Neuropharmacology
. 2002 Oct;
43(5):817-24.
PMID: 12384167
PNU-96391A is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. Previous experiments revealed that PNU-96391A antagonizes the expression of L-DOPA induced behavioral sensitization (dyskinesias) in lesioned primates...
4.
Pirker W, Tedroff J, Ponten H, Gunne L, Andren P, Hurd Y
Exp Neurol
. 2001 Apr;
169(1):122-34.
PMID: 11312565
The substituted phenylpiperidine (-)-OSU6162 is a novel modulator of the dopaminergic systems with low affinity for dopamine D(2) receptors and potent normalizing effects on l-DOPA-induced dyskinesias. We studied the effects...
5.
Carlsson A, Waters N, Tedroff J, Nilsson M, Carlsson M
Annu Rev Pharmacol Toxicol
. 2001 Mar;
41:237-60.
PMID: 11264457
In spite of its proven heuristic value, the dopamine hypothesis of schizophrenia is now yielding to a multifactorial view, in which the other monoamines as well as glutamate and GABA...
6.
Hadj Tahar A, Ekesbo A, Gregoire L, Bangassoro E, Svensson K, Tedroff J, et al.
Eur J Pharmacol
. 2001 Feb;
412(3):247-54.
PMID: 11166288
(S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine ((-)-OSU6162) is a phenylpiperidine derivative which exhibits low affinity to the dopamine D2 receptor in vitro. However, in vivo, positron emission tomography scanning studies show that the compound displaces...
7.
Ekesbo A, Andren P, Gunne L, Sonesson C, Tedroff J
Eur J Pharmacol
. 2000 Feb;
389(2-3):193-9.
PMID: 10688984
The effects of the novel compound, (-)-OSU6162 ((S)-(-)-3-methylsulfonylphenyl-1-propylpiperidine), on rotational behavior induced by dopamine receptor agonists was investigated in common marmosets (Callithrix jacchus) with unilateral 6-hydroxydopamine lesions. (-)-OSU6162 per se...
8.
Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A
Neurology
. 1999 Oct;
53(7):1605-6.
PMID: 10534281
No abstract available.
9.
Torstenson R, Tedroff J, Hartvig P, Fasth K, Langstrom B
J Cereb Blood Flow Metab
. 1999 Oct;
19(10):1142-9.
PMID: 10532639
11C-labeled 3,4-Dihydroxy-phenyl-L-alanine (L-DOPA) and L-fluorodopa were used as tracers for the functional state of the presynaptic dopamine system in anesthetized monkeys with positron emission tomography. The radiotracer disposition in brain...
10.
Tedroff J, Ekesbo A, Rydin E, Langstrom B, Hagberg G
Ann Neurol
. 1999 Sep;
46(3):359-65.
PMID: 10482266
Parkinson's disease (PD) is characterized by an uneven and progressive loss of nigrostriatal dopaminergic neurons. It is hypothesized that the physiological basis for the therapeutic response in early stages of...